Oxford Biomedica PLC
1 November 2001
Oxford BioMedica ('the Company')
Director's Dealings
Pursuant to the announcement made on 29 May 2001 regarding Dr. Doug Jolly's
subscription for 50,000 shares of 1p each ('Ordinary Shares') the Company
announces that on Friday 26 October 2001 it allotted the 50,000 Ordinary
Shares at a subscription price of 53.5 pence per share to Dr. Doug Jolly, CEO
of the Company's US operation, BioMedica Inc.
Following this allotment Dr. Jolly is interested in 50,000 Ordinary Shares,
representing 0.02% of the Company's current issued ordinary share capital.
Application for the listing of the Ordinary Shares has been made and admission
to listing is expected on Tuesday 6 November 2001.
FURTHER INFORMATION
Andrew Wood, Oxford BioMedica 01865 783000
1 November 2001
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.